Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal Injury
Key facts
- Who runs it
- First Affiliated Hospital of Zhejiang University
- Where
- China6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 15 Feb 2026
- Expected to end
- 15 Mar 2030
- Type of study
- Observational, 2 groups
- Record updated
- 7 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- -
- For Sepsis Patients:
- Age ≥ 18 years;
- Admitted to the Intensive Care Unit (ICU) and meets the Sepsis-3 diagnostic criteria (an acute change in total Sequential Organ Failure Assessment [SOFA] score ≥ 2 points consequent to the infection)
- Diagnosed with sepsis within 24 hours prior to enrollment
- Informed consent signed by the patient or a legally authorized representative; For Healthy Volunteers:
- Age ≥ 18 years
- No chronic underlying diseases (including liver, kidney, gastrointestinal, or immune-related disorders)
- No use of antibiotics or probiotics, and no history of acute infection within 1 month prior to enrollment (to ensure baseline consistency)
- Informed consent signed by the volunteer
Who cannot take part
- History of inflammatory bowel disease (including ulcerative colitis and Crohn's disease) or previous major intestinal resection
- Patients with malignant tumors currently receiving chemotherapy or radiotherapy
- Concurrent participation in other interventional clinical trials
- History of chronic liver disease (e.g., cirrhosis, chronic hepatitis B/C, autoimmune hepatitis, hepatic carcinoma)
- History of chronic kidney disease (e.g., glomerulonephritis, IgA nephropathy)
- Expected survival time of less than 72 hours
- Pregnant or lactating women
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a major cause of morbidity and mortality in intensive care units. Sepsis-associated liver injury (SALI) and sepsis-associated acute kidney injury (S-AKI) are common complications associated with adverse clinical outcomes. Altered gut microbial diversity, microbial metabolites, intestinal barrier dysfunction, and systemic inflammation may contribute to hepato-renal injury during sepsis. However, prospective longitudinal evidence in patients with SALI and S-AKI remains limited.
Read full original descriptionShow less
This prospective, multicenter, longitudinal observational cohort study will enroll adult patients with sepsis across eight intensive care units at six medical centers and healthy adult volunteers as a baseline reference cohort. For patients with sepsis, stool and blood samples will be collected on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis. Healthy volunteers will provide a single baseline stool and blood sample at enrollment. Fecal microbial alpha diversity and community structure will be assessed by metagenomic sequencing and bioinformatic analysis. Plasma metabolites, including total short-chain fatty acids, indoxyl sulfate, and additional targeted plasma metabolites, will be measured by ultra-high-performance liquid chromatography-tandem mass spectrometry. Intestinal barrier and clinical biomarkers will also be assessed.
The primary objectives are to evaluate the associations between longitudinal trajectories of fecal microbial alpha diversity, measured by the Shannon diversity index, and the occurrence of SALI and S-AKI within 7 days after sepsis diagnosis. Secondary objectives include evaluating the associations between longitudinal changes in fecal microbial beta diversity and the occurrence of SALI and S-AKI; assessing the associations between longitudinal trajectories of fecal microbial alpha diversity and organ recovery status at Days 14-20 among patients who develop SALI or S-AKI; describing selected plasma metabolite and intestinal biomarker concentrations at prespecified time points; and assessing 28-day all-cause mortality. Exploratory multi-omics analyses will evaluate microbial taxa, microbial functional genes, metabolites, and host biomarkers to identify candidate biomarkers and biological pathways associated with the development and clinical course of sepsis-associated hepato-renal injury.
The 2 groups in the trial
- Sepsis Patients
Adult patients (age ≥18 years) admitted to the ICU who meet the Sepsis-3 diagnostic criteria are enrolled within 24 hours after sepsis diagnosis. This cohort will be longitudinally monitored with biospecimen collection at four time points (Day 0, Days 3-5, Days 7-10, and Days 14-20). Based on clinical progression from Day 0 through Day 7 after sepsis diagnosis, participants will be classified according to the presence or absence of sepsis-associated liver injury (SALI) and sepsis-associated acute kidney injury (S-AKI) for outcome-specific comparative analyses. Participants with neither SALI nor S-AKI will constitute the Sepsis Control subgroup. Participants meeting criteria for both SALI and S-AKI will be included in both outcome-specific analyses. Among participants who develop SALI and/or S-AKI, organ recovery status will also be evaluated at Days 14-20 after sepsis diagnosis.
- Healthy Volunteers
Healthy adult volunteers (age ≥ 18 years) without chronic underlying diseases (e.g., liver, kidney, or gastrointestinal disorders) and no history of antibiotic or probiotic use within the past month. This cohort serves as a baseline reference cohort to characterize reference gut microbial and metabolic profiles; biospecimens will be collected only once at the time of enrollment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Association of Gut Microbiota With Sepsis-Associated Acute Hepatorenal Injury: A Prospective, Multicenter, Observational Study
- Record updated
- 7 October 2026